S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
S&P 500   3,943.86 (+0.69%)
DOW   32,173.91 (+0.98%)
QQQ   304.70 (-0.22%)
AAPL   157.48 (+1.60%)
MSFT   270.79 (-3.09%)
META   197.26 (+0.84%)
GOOGL   101.15 (-0.46%)
AMZN   97.07 (-1.90%)
TSLA   183.47 (+1.85%)
NVDA   258.57 (+0.51%)
NIO   8.72 (+5.57%)
BABA   80.88 (-0.97%)
AMD   96.17 (-1.71%)
T   18.45 (+1.77%)
F   11.20 (-0.88%)
MU   57.20 (+0.95%)
CGC   1.87 (-6.50%)
GE   89.88 (-0.45%)
DIS   93.74 (+0.58%)
AMC   4.30 (+2.87%)
PFE   40.61 (+1.27%)
PYPL   72.61 (-0.52%)
NFLX   303.91 (+0.14%)
Positive News Sentiment  
NASDAQ:HRMY

Harmony Biosciences - HRMY Price Target & Analyst Ratings

$44.87
+2.95 (+7.04%)
(As of 03/20/2023 02:46 PM ET)
Add
Compare
Today's Range
$41.82
▼
$45.17
50-Day Range
$40.64
▼
$49.88
52-Week Range
$33.04
▼
$62.08
Volume
750,021 shs
Average Volume
628,379 shs
Market Capitalization
$2.68 billion
P/E Ratio
15.11
Dividend Yield
N/A
Price Target
$61.89

Harmony Biosciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$61.89
37.93% Upside
High Prediction$70.00
Average Prediction$61.89
Low Prediction$43.00
TypeCurrent
3/20/22 to 3/20/23		1 Month Ago
2/18/22 to 2/18/23		3 Months Ago
12/20/21 to 12/20/22		1 Year Ago
3/20/21 to 3/20/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$61.89$63.33$62.50$53.25
Predicted Upside37.93% Upside19.42% Upside17.83% Upside49.99% Upside
Get Harmony Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.

HRMY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HRMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Harmony Biosciences Stock vs. The Competition

TypeHarmony BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside47.64% Upside3,856.53% Upside24.74% Upside
News Sentiment RatingVery Positive News
Neutral News
Neutral News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/22/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral$49.00 ➝ $43.00-1.85%
2/22/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$70.00 ➝ $60.00+36.96%
2/21/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$70.00+56.85%
1/4/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight$62.00 ➝ $70.00+32.18%
11/3/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$60.00 ➝ $62.00+3.32%
10/14/2022Janney Montgomery Scott
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$57.00 ➝ $61.00+28.07%
10/14/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$57.00 ➝ $61.00+28.07%
8/3/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$62.00 ➝ $67.00+28.75%
4/14/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOverweight$63.00+23.89%
(Data available from 3/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HRMY Price Target - Frequently Asked Questions

What is Harmony Biosciences's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Harmony Biosciences stock is Moderate Buy based on the current 1 hold rating and 8 buy ratings for HRMY. The average twelve-month price prediction for Harmony Biosciences is $61.89 with a high price target of $70.00 and a low price target of $43.00. Learn more on HRMY's analyst rating history.

Do Wall Street analysts like Harmony Biosciences more than its competitors?

Analysts like Harmony Biosciences more than other Medical companies. The consensus rating for Harmony Biosciences is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how HRMY compares to other companies.

Does Harmony Biosciences's stock price have much upside?

According to analysts, Harmony Biosciences's stock has a predicted upside of 25.63% based on their 12-month price targets.

What analysts cover Harmony Biosciences?

Harmony Biosciences has been rated by Mizuho, Needham & Company LLC, Piper Sandler, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:HRMY) was last updated on 3/20/2023 by MarketBeat.com Staff